IP Library Granted Patent US 11,291,628
Granted Patent B2
US 11,291,628 · App. 15/215,804 · Granted Apr 5, 2022

Chewable pharmaceutical product for delivery of colesevelam hydrochloride

Inventor: Tommy L. Chau (Ashburn, VA)
Assignee: Cosette Pharmaceuticals, Inc.
A61K9/0056A61K9/145A61K31/785A61P3/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,291,628
App. No.
15/215,804
Granted
Apr 5, 2022
Kind
B2
Abstract

A chewable pharmaceutical product comprises a matrix comprising: a binder, a bulking agent, a lubricant, a humectant, an emulsifier, and optionally a flavoring, wherein the binder comprises one or more maltitol syrups, which are present in the pharmaceutical product in an amount in the range of 60-70% by weight; and colesevelam hydrochloride.

Claims (40)

1. A chewable pharmaceutical product comprising:

a matrix comprising: a binder, a bulking agent, a lubricant, a humectant, an emulsifier, and optionally one or more of a flavoring, a coloring, and an antioxidant, wherein the binder comprises one or more maltitol syrups that are present in the pharmaceutical product in an amount in the range of 60-70% by weight; and

colesevelam hydrochloride wherein the maltitol syrup comprises two maltitol syrups: a first maltitol syrup having a higher solids content than a second maltitol syrup, which are present in a weight ratio (first maltitol syrup:second maltitol syrup) of from 2:1 to 4:1, which in combination, have an effective solids content in the range of 81.5-83.3%.

2. The chewable pharmaceutical product of claim 1 , wherein the colesevelam hydrochloride is present in a dosage of 3.75 grams±10%.

3. The chewable pharmaceutical product of claim 2 in the form of a bar having a unit weight of 30 g±10%.

4. The chewable pharmaceutical product of claim 1 , wherein the colesevelam hydrochloride is present in a dosage of 625 milligrams±10%.

5. The chewable pharmaceutical product of claim 4 in the form of a chew having a unit weight of 5 g±10%.

6. The chewable pharmaceutical product of claim 1 , wherein the bulking agent is sugar-free, comprising one or more of: sorbitol, mannitol, xylitol, lactitol, maltitol, isomalt, erythritol, polydextrose, maltodextrin, gelatin, gum acacia, carrageenan, locust bean gum, and guar gum.

7. The chewable pharmaceutical product of claim 1 , wherein the lubricant comprises palm oil, cocoa butter, sunflower oil, or combinations thereof.

8. The chewable pharmaceutical product of claim 1 , wherein the emulsifier comprises: lecithin, distilled monoglycerides, mono-diglycerides, distilled propylene glycol monoester, succinylated monoglycerides, glyceryl monostearate, diacetyl tartaric acid esters of mono-diglycerides, glycerol lacto palmitates, polyglycerol esters, stearol lactylates, sorbitan esters of polysorbates, or combinations thereof.

9. The chewable pharmaceutical product of claim 1 , wherein the humectant comprises: glycerin, propylene glycol, or combinations thereof.

10. The chewable pharmaceutical product of claim 1 , comprising the flavoring that comprises: chocolate flavor, vanilla flavor, strawberry flavor, caramel flavor, or combinations thereof.

11. The chewable pharmaceutical product of claim 1 comprising by weight of the pharmaceutical product:

(a) colesevelam hydrochloride in an amount of 3.75 grams±10%;

(b) maltitol syrup as the binder in an amount in the range of 63-66%;

(c) one or more of: maltodextrin and gum acacia as the bulking agent totaling an amount in the range of 5-15%;

(d) palm oil as the lubricant in an amount in the range of 1.5-6%;

(e) glycerin as the humectant in an amount in the range of 1-3%;

(f) lecithin as the emulsifier in an amount in the range of 1-2%;

(g) a flavoring in an amount in the range of 0.01-6%; and

(h) optionally one or more of a powdered sweetener, a coloring, and an antioxidant.

12. The chewable pharmaceutical product of claim 1 comprising by weight of the pharmaceutical product:

(a) colesevelam hydrochloride in an amount of 12.5%;

(b) maltitol solids in an amount in the range of 52-54%;

(c) one or more of: maltodextrin and gum acacia as the bulking agent totaling an amount in the range of 5-15%;

(d) palm oil as the lubricant in an amount in the range of 1.5-6%;

(e) glycerin as the humectant in an amount in the range of 1-3%;

(f) lecithin as the emulsifier in an amount in the range of 1-2%;

(g) a flavoring in an amount in the range of 0.01-6%;

(h) water in an amount in the range of 11.5-12.5%; and

(i) optionally one or more of a powdered sweetener, a coloring, and an antioxidant;

wherein ingredients (a)-(i) total 100%.

13. The chewable pharmaceutical product of claim 1 comprising the colesevelam hydrochloride in an amount of 12.5% by weight.

14. The chewable pharmaceutical product of claim 13 comprising by weight of the pharmaceutical product: colesevelam hydrochloride in an amount of 12.5%; maltitol solids in an amount in the range of 52-54%; water in an amount in the range of 11.5-12.5%; and the balance comprising a bulking, a lubricant, a humectant, an emulsifier, a flavoring, and optionally one or more of a powdered sweetener, a coloring, and an antioxidant.

15. A chewable pharmaceutical product comprising:

a matrix comprising: a binder, a bulking agent, a lubricant, a humectant, an emulsifier, and optionally one or more of a flavoring, a coloring, and an antioxidant, wherein the binder comprises one or more maltitol syrups that are present in the pharmaceutical product in an amount in the range of 60-70% by weight; and

colesevelam hydrochloride, wherein water content of the product is provided only by the one or more maltitol syrups and the colesevelam hydrochloride.

16. A method of delivering colesevelam hydrochloride comprising:

administering the chewable pharmaceutical product of claim 1 to a patient in need of glycemic control or lipid-lowering.

17. The method of claim 16 , wherein the chewable pharmaceutical product is ingested once per day.

Assignments (9)
PATENT SECURITY AGREEMENT Recorded Jul 9, 2024
From: COSETTE PHARMACEUTICALS, INC.
To: UBS AG, STAMFORD BRANCH, AS ADMINISTRATIVE AGENT
Reel/Frame 068257/0824 →
RELEASE OF SECURITY INTEREST Recorded Jun 26, 2024
From: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
To: COSETTE PHARMACEUTICALS, INC.
Reel/Frame 067848/0790 →
SECURITY INTEREST Recorded Jun 26, 2024
From: COSETTE PHARMACEUTICALS, INC.; MYRIEL PHARMACEUTICALS, LLC
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 067849/0095 →
PATENT SECURITY AGREEMENT Recorded Apr 26, 2023
From: COSETTE PHARMACEUTICALS, INC.
To: WELLS FARGO BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 063470/0372 →
SECURITY INTEREST Recorded Mar 16, 2022
From: COSETTE PHARMACEUTICALS, INC.
To: WELLS FARGO BANK, N.A., ADMINISTRATIVE AGENT
Reel/Frame 059287/0448 →
SECURITY INTEREST Recorded Mar 10, 2022
From: COSETTE PHARMACEUTICALS, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 059225/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2022
From: DAIICHI SANKYO, INC.
To: COSETTE PHARMACEUTICALS, INC.
Reel/Frame 058610/0351 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2016
From: CHAU, TOMMY L.
To: NUTRAVAIL LLC
Reel/Frame 039781/0929 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2016
From: NUTRAVAIL LLC
To: DAIICHI SANKYO, INC.
Reel/Frame 039781/0992 →
Continuity (1)
Related Publication 20180021255A1 · Jan 25, 2018